Alexander's(ALX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALX Alexander's

Trading 04-15 15:30:58 EDT

245.88

+0.08

+0.03%

High247.50	Low244.43	Vol22.26K
Open244.91	D1 Closing245.80	Amplitude1.25%
Mkt Cap1.26B	Tradable Cap522.66M	Total Shares5.11M
T/O5.47M	T/O Rate1.05%	Tradable Shares2.13M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALX","market":"US","secType":"STK","nameCN":"Alexander's","latestPrice":245.88,"timestamp":1776281436183,"preClose":245.8,"halted":0,"volume":22255,"delay":0,"changeRate":0.00032546786004875543,"floatShares":2125671,"shares":5107290,"eps":5.5,"marketStatus":"Trading","change":0.08,"latestTime":"04-15 15:30:58 EDT","open":244.905,"high":247.5,"low":244.43,"amount":5469287.094649999,"amplitude":0.01249,"askPrice":245.88,"askSize":1,"bidPrice":245.01,"bidSize":11,"shortable":3,"etf":0,"ttmEps":5.5,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1776283200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":-7416000000,"exchange":"NYSE","adjPreClose":245.8,"dividendRate":0.073176,"postHourTrading":{"tag":"盘后","latestPrice":245.57928,"preClose":245.8,"latestTime":"16:19 EDT","volume":438,"amount":107613.60736,"timestamp":1776197991688,"change":-0.22072,"changeRate":-0.000898,"amplitude":0.000898},"volumeRatio":0.58914},"requestUrl":"/m/hq/s/ALX/tweets","defaultTab":"tweets","newsList":[{"id":"2627445945","title":"ALX Oncology Names Jeff Knight Chief Development, Operating Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2627445945","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627445945?lang=en_us&edition=fundamental","pubTime":"2026-04-13 22:17","pubTimestamp":1776089823,"startTime":"0","endTime":"0","summary":"ALX Oncology  said Monday it named Jeff Knight as chief development and operating officer, effective immediately.The company said Knight most recently served in the same role at Crinetics Pharmaceuticals .Shares of ALX were up over 8% in Monday trading.Price: 1.88, Change: +0.18, Percent Change: +10.59","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627458272","title":"Press Release: ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2627458272","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627458272?lang=en_us&edition=fundamental","pubTime":"2026-04-13 20:30","pubTimestamp":1776083400,"startTime":"0","endTime":"0","summary":"- Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution. SOUTH SAN FRANCISCO, Calif., April 13, 2026  -- ALX Oncology Holdings Inc. , a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, announced the appointment of Jeff Knight, M.P.H., as Chief Development and Operating Officer, effective April 13, 2026.\"Jeff is a highly accomplished leader with deep expertise across clinical development and operations, and a strong track record of both advancing innovative therapies through critical stages of growth and advancing companies of our stage through late-stage development and commercialization,\" said Jason Lettmann, Chief Executive Officer at ALX Oncology. \"We anticipate several important catalysts in the next 12 to 18 months with our evorpacept and ALX2004 clinical programs. Jeff's leadership will be instrume","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Press Release: ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625896576","title":"Alexander’s announces annual shareholder meeting via virtual webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2625896576","media":"Reuters","labels":["conferences","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625896576?lang=en_us&edition=fundamental","pubTime":"2026-04-08 04:16","pubTimestamp":1775592992,"startTime":"0","endTime":"0","summary":"Alexander’s schedules virtual annual shareholder meeting for May 21, 2026.Shareholders will vote on election of three directors.Ballot includes approval of 2026 omnibus stock plan.Meeting also includes advisory vote on executive compensation.Investors will vote on ratification of Deloitte & Touche as independent auditor for 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alexander's Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 07, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL2hY15h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","BK4080","ALX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624553165","title":"Alexander's 731 Office One unit grants Bloomberg $57 million rent abatement at 731 Lexington Ave","url":"https://stock-news.laohu8.com/highlight/detail?id=2624553165","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624553165?lang=en_us&edition=fundamental","pubTime":"2026-04-01 05:18","pubTimestamp":1774991896,"startTime":"0","endTime":"0","summary":"Alexander’s unit 731 Office One LLC amended Bloomberg lease at 731 Lexington Avenue property.Lease amendment grants rent abatement of $57 million for April 1, 2026 to Dec. 1, 2026.Tenant improvement fund cut by $57 million to $57 million.Loan agreement amendment set up free rent reserve account of $57 million, with about $54 million already held.Reserve funds will cover monthly debt service during abatement period, with excess disbursed to Alexander’s.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alexander's Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 31, 2026, and is sol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLbxjJYn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALX","BK4194","BK4080","VNO","BK4588","BK4231","BK4223","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621034142","title":"ALX Oncology CEO Makes Notable Move With Latest Stock Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2621034142","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621034142?lang=en_us&edition=fundamental","pubTime":"2026-03-24 10:04","pubTimestamp":1774317874,"startTime":"0","endTime":"0","summary":"New insider activity at ALX Oncology Holdings ( ($ALXO) ) has taken place on March 23, 2026. ALX Oncology Holdings has seen insider activity, as CE...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/alx-oncology-ceo-makes-notable-move-with-latest-stock-sale-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/alx-oncology-ceo-makes-notable-move-with-latest-stock-sale-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4231","BK4080","ALX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620332225","title":"ALX Oncology Initiated at Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2620332225","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620332225?lang=en_us&edition=fundamental","pubTime":"2026-03-19 21:12","pubTimestamp":1773925920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALXO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 19, 2026 09:12 ET (13:12 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620805242","title":"Wells Fargo Initiates ALX Oncology at Overweight With $5 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2620805242","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620805242?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:26","pubTimestamp":1773919617,"startTime":"0","endTime":"0","summary":"ALX Oncology Holdings (ALXO) has an average rating of buy and mean price target of $4.60, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618680937","title":"ALX Oncology Price Target Maintained With a $4.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2618680937","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618680937?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:48","pubTimestamp":1773143280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALXO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 10, 2026 07:48 ET (11:48 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618628865","title":"BRIEF-Alexander's To Sell Rego Park I For Net Proceeds Of $202 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618628865","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618628865?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:12","pubTimestamp":1773054753,"startTime":"0","endTime":"0","summary":"BRIEF-Alexander's To Sell Rego Park I For Net Proceeds Of $202 MillionMarch 9 (Reuters) - Alexander's Inc ALX.N:ALEXANDER'S INC - ALEXANDER’S TO SELL REGO PARK I FOR NET PROCEEDS OF $202 MILLIONFurther company coverage: ALX.N ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nFWN3ZX0MM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","BK4231","ALX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617701596","title":"Should Atlas Arteria's 20c Payout Amid Softer Earnings Shift the Income Trade-Off for (ASX:ALX) Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2617701596","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617701596?lang=en_us&edition=fundamental","pubTime":"2026-03-05 08:52","pubTimestamp":1772671945,"startTime":"0","endTime":"0","summary":"Atlas Arteria Limited has reported its full-year 2025 results, with revenue of A$160.0 million and net income of A$259.5 million, and declared a 20.0 cent per security distribution for the second half of 2025, payable in April 2026.\nThe combination of higher revenue but lower net income and earnings per share compared with the previous year, alongside the confirmed distribution, gives investors a clearer view of the trade-off between current income and recent profitability trends.\nWe will...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/3252000-choice2-main-header/1585187464700","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3252000-choice2-main-header/1585187464700"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/transportation/asx-alx/atlas-arteria-shares/news/should-atlas-arterias-20c-payout-amid-softer-earnings-shift","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/transportation/asx-alx/atlas-arteria-shares/news/should-atlas-arterias-20c-payout-amid-softer-earnings-shift","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ISBC","ALX","ALX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616374496","title":"Assessing Atlas Arteria (ASX:ALX) Valuation After 2025 Earnings Update And Second Half Distribution","url":"https://stock-news.laohu8.com/highlight/detail?id=2616374496","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616374496?lang=en_us&edition=fundamental","pubTime":"2026-03-04 02:37","pubTimestamp":1772563037,"startTime":"0","endTime":"0","summary":"Atlas Arteria (ASX:ALX) has drawn attention after reporting full year 2025 results, with revenue of A$160 million, net income of A$259.5 million and earnings per share easing alongside a 20 cent second half distribution declaration.\nSee our latest analysis for Atlas Arteria.\nAtlas Arteria’s A$4.76 share price reflects a modest 1-year total shareholder return of 2.42%, while the 3-year total shareholder return decline of 11.16% suggests momentum has been softer despite the latest earnings and...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/3252000-choice2-main-header/1585187464700","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3252000-choice2-main-header/1585187464700"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/transportation/asx-alx/atlas-arteria-shares/news/assessing-atlas-arteria-asxalx-valuation-after-2025-earnings","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/transportation/asx-alx/atlas-arteria-shares/news/assessing-atlas-arteria-asxalx-valuation-after-2025-earnings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ALX","ALX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616286313","title":"Compass Diversified Holdings Adds Eugene Kim and Glenn Richter to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2616286313","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616286313?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:10","pubTimestamp":1772543415,"startTime":"0","endTime":"0","summary":"Compass Diversified Holdings said Eugene Kim and Glenn Richter were elected to its board effective March 1, 2026, expanding the board to eight directors. Alexander S. Bhathal resigned effective Feb. 28, 2026. Kim will serve on the Audit and Compensation Committees, while Richter will serve on the Audit and Nominating and Corporate Governance Committees.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL2Lb1cQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CODI","IE00B64PRP62.GBP","LU2095319765.USD","NDAQ","ALX","BK4223","SG9999014005.SGD","BK4588","BK4231","BK4194","LU0314104364.USD","SG9999014013.SGD","BK4112","BK4176","SG9999014039.USD","BK4585","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","BK4080","VNO","IE00BKPKM429.USD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616820859","title":"Assessing Alexander’s (ALX) Valuation After Vacancies Plan And Refinancing Shift Investor Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2616820859","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616820859?lang=en_us&edition=fundamental","pubTime":"2026-03-01 21:16","pubTimestamp":1772371017,"startTime":"0","endTime":"0","summary":"Recent commentary on Alexander's (ALX) argues that its vacant retail space is part of a plan to unlock value, not lasting damage, with a refinancing improving liquidity and supporting ongoing dividend payments.\nSee our latest analysis for Alexander's.\nAt a share price of $234.62, Alexander's has seen a 9.86% 90 day share price return and a 7.20% year to date share price return, while the 1 year total shareholder return sits at 18.67%, which reflects recent performance across different time...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551736-choice2-main-header/1585186602415","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551736-choice2-main-header/1585186602415"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/real-estate/nyse-alx/alexanders/news/assessing-alexanders-alx-valuation-after-vacancies-plan-and","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/real-estate/nyse-alx/alexanders/news/assessing-alexanders-alx-valuation-after-vacancies-plan-and","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","ALX.AU","ALX","BK4231","BK7090","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614285160","title":"ALX Oncology Holdings Q4 Adj. EPS $(0.37) Misses $(0.36) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2614285160","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614285160?lang=en_us&edition=fundamental","pubTime":"2026-02-27 22:03","pubTimestamp":1772201024,"startTime":"0","endTime":"0","summary":"ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.36) by 2.21 percent. This is a 15.91 percent increase over losses of $(0.44) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50926754/alx-oncology-holdings-q4-adj-eps-0-37-misses-0-36-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALXO","ALX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614611859","title":"ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2614611859","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614611859?lang=en_us&edition=fundamental","pubTime":"2026-02-27 21:00","pubTimestamp":1772197200,"startTime":"0","endTime":"0","summary":"- Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/27/3246481/0/en/ALX-Oncology-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","OS","BK4231","ADC","BK4144","LU0266512127.USD","PFS","IE00BMG7P694.USD","BK4097","IE00BD4GTT62.SGD","IE00BMG7P702.HKD","IE00BMG7P819.SGD","SITC","IE00BD4GTV84.USD","BK4195","BK4203","ASH","BK4109","IE00BMG7P926.USD","LU2463526074.USD","BK4566","CR","BK4080","IE00BD4GTW91.USD","BK4225","TRP","LU0456854461.SGD","BK4213","HR","IE00BMG7P587.USD","ALX","BK4161","ORR","CRC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612400749","title":"Press Release: ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2612400749","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612400749?lang=en_us&edition=fundamental","pubTime":"2026-02-19 21:30","pubTimestamp":1771507800,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026  -- ALX Oncology Holdings Inc. , a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced plans to report its fourth quarter and full year 2025 financial results and a business update on Friday, February 27th, 2026 before market open. The company will host a teleconference in conjunction with its financial results press release.Fourth Quarter and Full Year 2025 Results Webcast Information. Date & Time: Friday, February 27, 2026 at 5:30am PT / 8:30am ET. Participant Listening Options by Phone: To access the conference call, please dial 1-877- 407-0755 or +1-201-389-0913 and ask to be joined into the ALX Oncology Fourth Quarter and Full Year 2025 Financial Results Conference Call.Another option for instant telephone access to the event is to use the Call me link below:","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALX","BK4604","BK4099","BK4139","ALXO","BK4080","BK4555","TM","BK4588","BK4231","BK4585","03160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610948458","title":"Alexander's Balances Weaker Earnings With Buybacks And Rising New York Occupancy","url":"https://stock-news.laohu8.com/highlight/detail?id=2610948458","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610948458?lang=en_us&edition=fundamental","pubTime":"2026-02-12 15:23","pubTimestamp":1770880980,"startTime":"0","endTime":"0","summary":"Alexander's Inc. (NYSE:ALX) reported lower quarterly and full year net income and funds from operations.\nManagement highlighted improving New York office occupancy as a key operational development.\nThe CEO pointed to share buybacks as a current priority, reflecting views on the stock's valuation.\n\nFor investors watching real estate investment trusts, Alexander's sits in an interesting spot. The stock trades at $230.02 and is up 25.6% over the past year and 29.0% over the past three years,...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551736-choice2-main-header/1585186602415","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551736-choice2-main-header/1585186602415"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/real-estate/nyse-alx/alexanders/news/alexanders-balances-weaker-earnings-with-buybacks-and-rising","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/real-estate/nyse-alx/alexanders/news/alexanders-balances-weaker-earnings-with-buybacks-and-rising","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ALX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610560598","title":"Alexander’s (ALX) FFO Drop In Q4 2025 Challenges Income Focused Bullish Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2610560598","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610560598?lang=en_us&edition=fundamental","pubTime":"2026-02-11 06:34","pubTimestamp":1770762859,"startTime":"0","endTime":"0","summary":"Alexander's (ALX) closed out FY 2025 with Q4 total revenue of US$53.3 million and basic EPS of US$0.74, alongside funds from operations of US$12.5 million. This puts the latest quarter in clear focus for income driven REIT investors. The company has seen quarterly revenue move from US$55.9 million and EPS of US$2.39 in Q4 2024 to US$53.3 million and EPS of US$0.74 in Q4 2025. Trailing twelve month net profit margin sat at 17% compared with 20.3% a year earlier as earnings slipped over a five...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551736-choice2-main-header/1585186602415","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551736-choice2-main-header/1585186602415"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/real-estate/nyse-alx/alexanders/news/alexanders-alx-ffo-drop-in-q4-2025-challenges-income-focused","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/real-estate/nyse-alx/alexanders/news/alexanders-alx-ffo-drop-in-q4-2025-challenges-income-focused","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ALX","BK4231","BLSX","BK4112","BK4080","BLSG","BK7090"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124131282","title":"Stock Track | Alexander's Plummets 5.44% Intraday After Q4 Earnings and Revenue Miss Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=1124131282","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124131282?lang=en_us&edition=fundamental","pubTime":"2026-02-09 22:34","pubTimestamp":1770647688,"startTime":"0","endTime":"0","summary":"Alexander's (ALX) stock plummeted 5.44% during intraday trading on Monday, following the release of its fourth-quarter financial results that fell short of analyst expectations.The real estate...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ALX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610656096","title":"Alexander's net income, revenue fall in Q4","url":"https://stock-news.laohu8.com/highlight/detail?id=2610656096","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610656096?lang=en_us&edition=fundamental","pubTime":"2026-02-09 22:26","pubTimestamp":1770647160,"startTime":"0","endTime":"0","summary":"Alexander's net income, revenue fall in Q4OverviewReal estate investment trust's Q4 revenue slightly missed analyst expectationsNet income for Q4 fell compared to last yearCompany's FFO for Q4 decreas","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nL1N3Z50L5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","BK4080","ALX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alx-inc.com","stockEarnings":[{"period":"1week","weight":0.0632},{"period":"1month","weight":0.0142},{"period":"3month","weight":0.0514},{"period":"6month","weight":0.0581},{"period":"1year","weight":0.2154},{"period":"ytd","weight":0.1278}],"compareEarnings":[{"period":"1week","weight":0.0535},{"period":"1month","weight":0.0486},{"period":"3month","weight":0.0059},{"period":"6month","weight":0.0512},{"period":"1year","weight":0.2881},{"period":"ytd","weight":0.0184}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alexander's, Inc. (NYSE: ALX) is a real estate investment trust (REIT), incorporated in Delaware, engaged in leasing, managing, developing and redeveloping its properties. All references to we, us, our, Company and Alexander's refer to Alexander's, Inc. and its consolidated subsidiaries. We are managed by, and our properties are leased and developed by, Vornado Realty Trust (Vornado) (NYSE: VNO). We have five properties in New York City.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.01062},{"month":2,"riseRate":0.456522,"avgChangeRate":0.003648},{"month":3,"riseRate":0.521739,"avgChangeRate":0.01662},{"month":4,"riseRate":0.446809,"avgChangeRate":0.007873},{"month":5,"riseRate":0.521739,"avgChangeRate":0.024688},{"month":6,"riseRate":0.5,"avgChangeRate":0.00582},{"month":7,"riseRate":0.586957,"avgChangeRate":0.014946},{"month":8,"riseRate":0.478261,"avgChangeRate":0.005583},{"month":9,"riseRate":0.5,"avgChangeRate":0.023298},{"month":10,"riseRate":0.521739,"avgChangeRate":0.013397},{"month":11,"riseRate":0.456522,"avgChangeRate":-0.006173},{"month":12,"riseRate":0.521739,"avgChangeRate":0.017167}],"exchange":"NYSE","name":"Alexander's","nameEN":"Alexander's"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alexander's(ALX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alexander's(ALX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alexander's,ALX,Alexander's股票,Alexander's股票老虎,Alexander's股票老虎国际,Alexander's行情,Alexander's股票行情,Alexander's股价,Alexander's股市,Alexander's股票价格,Alexander's股票交易,Alexander's股票购买,Alexander's股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alexander's(ALX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alexander's(ALX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction